1-20 of 148
David A. Sallman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 1/1b Safety Study of Prgn-3006 Ultracar-T in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

David A. Sallman, Hany Elmariah, Kendra Sweet, Asmita Mishra, Cheryl A Cox, Marion Chakaith, Roshanak Semnani, Sheeba Shehzad, Asha Anderson, Helen Sabzevari, Amy Lankford, Onyee Chan, Luis SanchezMolina, Chen Wang, Eric Padron, Andrew Kuykendall, Rami S. Komrokji, Jeffrey E. Lancet, Marco L. Davila, Nelli Bejanyan
Journal: Blood
Blood (2022) 140 (Supplement 1): 10313–10315.
DOI: https://doi.org/10.1182/blood-2022-169142
Published: 2022
Journal Articles

Discordance between Patient Goals and Treatment in Older AML Patients

Sara Marie Tinsley-Vance, Cecile A. Lengacher, Andrew Kuykendall, Daniel Lastorino, Amaya Oyola, Onyee Chan, Eric Padron, Areej El-Jawahri, David A. Sallman, Kendra Sweet, Jeffrey E. Lancet, Rami S. Komrokji
Journal: Blood
Blood (2022) 140 (Supplement 1): 8133–8135.
DOI: https://doi.org/10.1182/blood-2022-163684
Published: 2022
Journal Articles

Secondary AML Mutations Confer Poor Prognosis in Patients with ELN Favorable Risk NPM1 -Mutated AML

Onyee Chan, Najla Al Ali, Hammad Tashkandi, Austin Ellis, Somedeb Ball, Justin Grenet, Caroline Hana, Yehuda E. Deutsch, Ling Zhang, Mohammad O Hussaini, Jinming Song, Seongseok Yun, Chetasi Talati, Andrew Kuykendall, Eric Padron, Alison R. Walker, Gail J. Roboz, Pinkal Desai, David A. Sallman, Kendra Sweet, Rami S. Komrokji, Jeffrey E. Lancet
Journal: Blood
Blood (2022) 140 (Supplement 1): 3419–3421.
DOI: https://doi.org/10.1182/blood-2022-165802
Published: 2022
Journal Articles

Validation of the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification Model for Myelodysplastic Syndromes

Luis E. Aguirre, Najla Al Ali, Somedeb Ball, Avani M Singh, Akriti G Jain, Onyee Chan, Zaker I. Schwabkey, Sara M Tinsley-Vance, Andrew Kuykendall, Kendra Sweet, Jeffrey E. Lancet, Eric Padron, David A. Sallman, Rami S. Komrokji
Journal: Blood
Blood (2022) 140 (Supplement 1): 1125–1127.
DOI: https://doi.org/10.1182/blood-2022-170878
Published: 2022
Journal Articles

How Many Stratification Factors Are Reasonable and Can There be Too Many? Evaluation of Analysis Strategies in the Context of a Randomized Phase 2 Trial in Acute Myeloid Leukemia within the Myelomatch Platform

Anna Moseley, Boris Freidlin, Rory Michael Shallis, Amer M. Zeidan, David A. Sallman, Richard F. Little, Harry P. Erba, Michael L. Leblanc, Megan Othus
Journal: Blood
Blood (2022) 140 (Supplement 1): 8932–8933.
DOI: https://doi.org/10.1182/blood-2022-170376
Published: 2022
Journal Articles

A Phase 2a/2b Multicenter Study of AG-946 in Patients with Anemia Due to Lower-Risk Myelodysplastic Syndromes

Hanny Al-Samkari, Pierre Fenaux, Mikkael A. Sekeres, Eytan Stein, David A. Sallman, Andrew M. Brunner, Xiaoshu D. Gurov, Ophelia Yin, Meghan Frisbie, James Xiao, Joy Bhatia, Vanessa Beynon, Megan Wind-Rotolo, Melissa Dibacco, Uwe Platzbecker
Journal: Blood
Blood (2022) 140 (Supplement 1): 4076–4078.
DOI: https://doi.org/10.1182/blood-2022-168907
Published: 2022
Journal Articles

Outcomes of Acute Myeloid Leukemia Relapsed Post-Allogeneic Hematopoietic Stem Cell Transplant Treated with Hypomethylating Agents and Venetoclax Combination: A Single Center Experience

Filip Ionescu, David A. Sallman, Kendra Sweet, Rami S. Komrokji, Onyee Chan, Andrew Kuykendall, Eric Padron, Rawan Faramand, Nelli Bejanyan, Farhad Khimani, Hany Elmariah, Joseph Pidala, Asmita Mishra, Lia Perez, Taiga Nishihori, Jeffrey E. Lancet
Journal: Blood
Blood (2022) 140 (Supplement 1): 1288–1290.
DOI: https://doi.org/10.1182/blood-2022-165661
Published: 2022
Journal Articles

Treatments and Outcomes for Patients at Academic Cancer Centers with Myelodysplastic Syndrome (MDS) By Revised International Prognostic Scoring System (IPSS-R) Scores

Connor Willis, David A. Sallman, Malinda Tan, Madeline Brendle, Vonetta L. Williams, Craig Comperatore, Trang Au, Srinivas K. Tantravahi, Najla Al Ali, Jeffrey A. Gilreath, Tibor Kovacsovics, Xiting Cao, Islam Sadek, Rami S. Komrokji, David Stenehjem
Journal: Blood
Blood (2022) 140 (Supplement 1): 5291–5292.
DOI: https://doi.org/10.1182/blood-2022-162622
Published: 2022
Journal Articles

Assessment of the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification Model in Therapy-Related Myelodysplastic Syndromes

Luis E. Aguirre, Najla Al Ali, Somedeb Ball, Avani M Singh, Akriti G Jain, Onyee Chan, Zaker I. Schwabkey, Sara M Tinsley-Vance, Andrew Kuykendall, Kendra Sweet, Jeffrey E. Lancet, Eric Padron, David A. Sallman, Rami S. Komrokji
Journal: Blood
Blood (2022) 140 (Supplement 1): 9813–9815.
DOI: https://doi.org/10.1182/blood-2022-170980
Published: 2022
Journal Articles

Post-Allogeneic Stem Cell Transplant Outcomes in Patients Treated with Hypomethylating Agent Plus Venetoclax Compared to CPX-351

Akriti G Jain, Somedeb Ball, Luis E.E. Aguirre, Andrew Kuykendall, Onyee Chan, Rami S. Komrokji, Eric Padron, David A. Sallman, Jeffrey E. Lancet, Asmita Mishra, Kendra Sweet
Journal: Blood
Blood (2022) 140 (Supplement 1): 1447–1449.
DOI: https://doi.org/10.1182/blood-2022-170807
Published: 2022
Journal Articles

The Prognostic Impact of FLT3 in NPM1 -Mutated AML: Co-Occurrence of FLT3-ITD and FLT3-TKD Confers Poor Outcomes

Onyee Chan, Najla Al Ali, Somedeb Ball, Justin Grenet, Caroline Hana, Yehuda E. Deutsch, Hammad Tashkandi, Ling Zhang, Mohammad O Hussaini, Seongseok Yun, Andrew Kuykendall, Eric Padron, Gail J. Roboz, Pinkal Desai, Rami S. Komrokji, Kendra Sweet, Jeffrey E. Lancet, David A. Sallman
Journal: Blood
Blood (2022) 140 (Supplement 1): 3435–3437.
DOI: https://doi.org/10.1182/blood-2022-171197
Published: 2022
Journal Articles

Ameli-01: A Phase I Trial of UCART123v1.2, an Anti-CD123 Allogeneic CAR-T Cell Product, in Adult Patients with Relapsed or Refractory (R/R) CD123+ Acute Myeloid Leukemia (AML)

David A. Sallman, Daniel J. DeAngelo, Naveen Pemmaraju, Shira Dinner, Saar Gill, Rebecca L. Olin, Eunice S. Wang, Marina Konopleva, Eileen Stark, Ana Korngold, Asifa Haider, Kate Backhouse, Carolyn Figliola, Daniel J. Lee, Mark G. Frattini, Carrie Brownstein, Gail J. Roboz
Journal: Blood
Blood (2022) 140 (Supplement 1): 2371–2373.
DOI: https://doi.org/10.1182/blood-2022-169928
Published: 2022
Journal Articles

Molecular Characterization of Clinical Response in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome Patients Treated with Single Agent Emavusertib

Klaus H. Metzeler, Eric S. Winer, Uwe Platzbecker, Amit Verma, Daniel J. DeAngelo, Stefano R. Tarantolo, David A. Sallman, James Dugan, Stefanie Gröpper, Katharina S. Goetze, Chia-Cheng Li, Wanying Zhao, Maureen Lane, Reinhard von Roemeling, Samantha Carlisle, Anne Weigert, Matthias Böhme, Anne Sophie Kubasch, Guillermo Garcia-Manero
Journal: Blood
Blood (2022) 140 (Supplement 1): 9048–9049.
DOI: https://doi.org/10.1182/blood-2022-167477
Published: 2022
Journal Articles

A Product of "Clash of Titans" or True Reflection of Disease Biology? Validation of 2022 WHO and ICC Classifications in a Large Dataset of Patients with Myelodysplastic Syndrome

Somedeb Ball, Avani M Singh, Najla Al Ali, Luis E. Aguirre, Akriti G Jain, Zaker I. Schwabkey, Sara M Tinsley-Vance, Onyee Chan, Andrew Kuykendall, Kendra Sweet, Jeffrey E. Lancet, Eric Padron, David A. Sallman, Rami S. Komrokji
Journal: Blood
Blood (2022) 140 (Supplement 1): 1118–1120.
DOI: https://doi.org/10.1182/blood-2022-170158
Published: 2022
Journal Articles

ASTX727-03: Phase 1 Study Evaluating Oral Decitabine/Cedazuridine (ASTX727) Low-Dose (LD) in Lower-Risk Myelodysplastic Syndromes (LR-MDS) Patients

Guillermo Garcia-Manero, Kimo Bachiashvili, Harshad Amin, Elie Traer, Daniel A. Pollyea, David A. Sallman, Aref Al-Kali, Larry D. Cripe, Jesus G Berdeja, Elizabeth A. Griffiths, Sanjay R Mohan, Yuri Sano, Aram Oganesian, Harold N. Keer, Abdulraheem Yacoub
Journal: Blood
Blood (2022) 140 (Supplement 1): 1112–1114.
DOI: https://doi.org/10.1182/blood-2022-156512
Published: 2022
Journal Articles

Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Naval Daver, Pau Montesinos, Ahmed Aribi, Giovanni Marconi, Jessica K. Altman, Eunice S. Wang, Gail J. Roboz, Patrick W. Burke, Gianluca Gaidano, Roland B. Walter, Xavier Thomas, Deepa Jeyakumar, Daniel J. DeAngelo, Harry P. Erba, Elisabetta Todisco, Kebede H. Begna, Anjali Advani, Lauris Gastaud, Adolfo De La Fuente, Antonio Curti, Lourdes M. Mendez, Paresh Vyas, Nicolas Boissel, Norbert Vey, Christian Recher, Thomas Longval, Uwe Platzbecker, Silke Kapp-Schwoerer, Christoph Schliemann, Marina Konopleva, Laura Torres, David A. Sallman, Guido Marcucci, Naveen Pemmaraju, Giovanni Martinelli, Hagop Kantarjian, Callum M Sloss, Kara E Malcolm, Patrick A Zweidler-McKay, Kendra Sweet
Journal: Blood
Blood (2022) 140 (Supplement 1): 145–149.
DOI: https://doi.org/10.1182/blood-2022-158030
Published: 2022
Journal Articles

Clinical Characterization and Outcomes of Patients with NPM1 -Mutated Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Chen Wang, Onyee Chan, Najla Al Ali, Andrew Kuykendall, Eric Padron, Kendra Sweet, Jeffrey E. Lancet, Rami S. Komrokji, David A. Sallman
Journal: Blood
Blood (2022) 140 (Supplement 1): 6936–6937.
DOI: https://doi.org/10.1182/blood-2022-160464
Published: 2022
Journal Articles

Nature of Clinical Response and Depth of Molecular Response in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Treated with Magrolimab with Azacitidine

Lisa Johnson, Yajia Zhang, Biao Li, Lisa Aviles, Indu Lal, Giri Ramsingh, Naval Daver, Paresh Vyas, David A. Sallman
Journal: Blood
Blood (2022) 140 (Supplement 1): 6934–6935.
DOI: https://doi.org/10.1182/blood-2022-160337
Published: 2022
Journal Articles

Luspatercept for Treatment of Lower Risk Myelodysplastic Syndromes: Real World Data Replicates Medalist Study Results and Confirms Activity Among Hypomethylating Agents and Lenalidomide Treated Patients

Rami S. Komrokji, Najla Al Ali, Somedeb Ball, Onyee Chan, Andrew Kuykendall, Kendra Sweet, Jeffrey E. Lancet, Eric Padron, David A. Sallman
Journal: Blood
Blood (2022) 140 (Supplement 1): 4039–4041.
DOI: https://doi.org/10.1182/blood-2022-169690
Published: 2022
Journal Articles

Characterization of TP53 -Mutated Myelodysplastic Syndromes and Impact of Allelic Status and Concurrent Cytogenetic Abnormalities on Survival Outcomes

Luis E. Aguirre, Najla Al Ali, Akriti G Jain, Onyee Chan, Somedeb Ball, Andrew Kuykendall, Kendra Sweet, Jeffrey E. Lancet, Eric Padron, Rami S. Komrokji, David A. Sallman
Journal: Blood
Blood (2022) 140 (Supplement 1): 4034–4035.
DOI: https://doi.org/10.1182/blood-2022-171093
Published: 2022